Anterogen is a bio-venture company specializing in research and development of cell therapy products and orphan drugs using adult stem cells.
Established a research institute in Boston in 2000, Anterogen began commercializing products using adipose-derived stem cells for the first time in Korea.
In January 2012, we obtained a market authorization of Cupistem® injection as an adipose-derived stem cell therapy product for the first time in the world.
Anterogen, an emerging global leader in the field of cell therapy products, has developed Adipocell® (for the treatment of depressed scar), Queencell® (for the regeneration of subcutaneous adipose tissue) and Cupistem® injection (for the treatment of Crohn's fistula) with accumulated experiences and R&D technology in stem cell therapy.
Company Details
- Employees
- 7
- Founded
- -
- Address
- #610, Digitalro 130, Gumcheon, Seoul,08589,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://anterogen.com/main/en/
- Keywords
- stemcell, orphandrug, stellcell cosmetics, K-bio.
- HQ
- Seoul
Anterogen Questions
Anterogen's website is http://anterogen.com/main/en/
Anterogen's LinkedIn profile is https://kr.linkedin.com/company/anterogen
Anterogen has
7 employees.
View email and phone details for 7
employees at Anterogen.
Anterogen's industry is
Biotechnology Research
Anterogen's categories are Biotechnology Research
Anterogen's founding year is 2000
